What Eli Lilly Said About the $50 Cap
Eli Lilly issued a significant warning on March 9, 2026. The pharmaceutical giant confirmed that a small number of basic Medicare Part D plans may not honor the widely publicized $50 per month out-of-pocket cap for its weight-loss drugs. This announcement came shortly after the Centers for Medicare and Medicaid Services (CMS) declared it had completed negotiations with both Lilly and Novo Nordisk under a new federal weight-loss drug coverage model.
Lilly stressed that most participating Medicare plan options will follow the $50 cap. However, beneficiaries enrolled in certain basic Part D plans could face higher costs. The company pledged to educate patients and physicians about plan choices and financial assistance programs to help minimize costs.
How the CMS BALANCE Model Works
A Voluntary Federal Coverage Program
The CMS launched the BALANCE model — a voluntary program designed to expand GLP-1 drug coverage for obesity and diabetes under Medicare and Medicaid. Under this framework, CMS directly negotiates standardized coverage terms and guaranteed net prices with drugmakers. The goal is to lower patient costs while bundling drug access with evidence-based lifestyle and behavioral support.
Why the Program Matters
GLP-1 drugs such as Zepbound, Mounjaro, and Wegovy typically carry list prices exceeding $1,000 per month for uninsured patients. Furthermore, even insured patients often face steep copays. The BALANCE model, therefore, represents a landmark shift in how the federal government addresses obesity treatment affordability. By capping costs and standardizing coverage, CMS aims to make these medications accessible to millions of Americans for the first time.
Which Medicare Plans May Charge More
The Exception, Not the Rule
According to Eli Lilly, the $50 cap applies to the majority of participating Medicare plans. Nevertheless, a small subset of basic Medicare Part D plans may not fully comply. Specifically, cost-sharing structures within these plans can vary — and in some cases, beneficiaries may pay more than $50 per month.
What Is Medicare Part D?
Medicare Part D is the prescription drug component of Medicare, administered through private insurance companies. Because private insurers design their own plan structures, some variation in cost-sharing is possible even within a federally negotiated program. This is why Eli Lilly is proactively alerting patients to check their individual plan terms before assuming the $50 cap applies.
What Drugs Are Covered and at What Cost
Lilly’s GLP-1 Portfolio Under the Model
Under the CMS agreement, the following Eli Lilly drugs are included:
- Zepbound (tirzepatide) — available in a multi-dose injectable pen
- Mounjaro (tirzepatide) — approved for diabetes but widely used for weight management
- Orforglipron — Lilly’s once-daily oral obesity pill, pending FDA approval
Pricing at a Glance
For most Medicare beneficiaries enrolled in compliant plans, the out-of-pocket cost is $50 per month. For those paying out of pocket through LillyDirect, Zepbound’s multi-dose pen starts at $299 per month at the lowest dose, with higher doses priced up to $449 — representing a $50 discount from previous direct-to-patient prices. Meanwhile, orforglipron’s starting dose is priced at $149 per month for Medicare and Medicaid beneficiaries once it receives FDA approval.
When Does Coverage Begin
A Phased Rollout
Coverage under the BALANCE model does not begin all at once. Instead, CMS has set a phased timeline:
- Medicaid coverage — expected to begin as early as May 2026
- Medicare Part D — scheduled to launch January 1, 2027
Additionally, CMS awarded Eli Lilly a Commissioner’s National Priority Voucher for orforglipron, which could accelerate the FDA approval process and bring the oral pill to market sooner. Once approved, orforglipron will also become available through LillyDirect for self-pay patients.
What Patients Should Do Now
Steps to Protect Your Out-of-Pocket Costs
Because not all basic Medicare Part D plans will honor the $50 cap, patients should take proactive steps. Here is what experts and Eli Lilly recommend:
- Review your current Part D plan — Check whether your specific plan is listed as a participating BALANCE model plan.
- Ask your physician — Lilly has committed to educating healthcare providers about plan options and patient assistance programs.
- Explore financial assistance — Lilly’s patient support programs may help bridge cost gaps for those in non-compliant plans.
- Look into Medicaid eligibility — For lower-income beneficiaries, Medicaid coverage starting May 2026 could provide a more affordable path.
The Bigger Picture for Obesity Drug Access
A Turning Point for Medicare Coverage
Historically, Medicare did not cover weight-loss drugs. Consequently, millions of Americans living with obesity were excluded from federal drug coverage for treatments that could meaningfully reduce their health risks. The BALANCE model changes this. Starting in 2026 and 2027, an estimated 20 to 30 million Medicare beneficiaries with obesity or related conditions could become eligible for GLP-1 treatments.
Broader Implications for Healthcare
Moreover, expanded Medicare coverage is expected to push private insurers to follow suit. As federal programs normalize GLP-1 reimbursement, the commercial insurance market may face growing pressure to cover these medications. This could dramatically reshape the obesity treatment landscape in the United States.
A Note on Novo Nordisk
Eli Lilly is not alone in this agreement. Novo Nordisk — maker of Wegovy and Ozempic — also completed negotiations with CMS under the same BALANCE model. Together, the two pharmaceutical giants represent the dominant share of the GLP-1 market, meaning the new coverage model will affect the vast majority of patients prescribed these drugs.
